Lung cancer at the intensive care unit: The era of targeted therapy
- 1 August 2015
- journal article
- case report
- Published by Elsevier BV in Lung Cancer
- Vol. 89 (2), 218-221
- https://doi.org/10.1016/j.lungcan.2015.05.009
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Ceritinib inALK-Rearranged Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2014
- Intensive Care Unit Outcomes Among Patients With Lung Cancer in the Surveillance, Epidemiology, and End Results–Medicare RegistryJournal of Clinical Oncology, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- The Outcome of Medical Intensive Care for Lung Cancer Patients: The Case for OptimismJournal of Thoracic Oncology, 2011
- Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unitSupportive Care in Cancer, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Outcome and prognostic factors of lung cancer patients admitted to the medical intensive care unitEuropean Respiratory Journal, 2008
- Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unitIntensive Care Medicine, 2005
- Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy*Critical Care Medicine, 2005